+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Is the use of beta-blockers in COPD still an unresolved dilemma?



Is the use of beta-blockers in COPD still an unresolved dilemma?



Respiration; International Review of Thoracic Diseases 80(3): 177-187



Beta-blockers are competitive antagonists at beta-adrenergic receptors (beta-AR) and are a life-saving form of treatment in different cardiovascular diseases (CVD). Despite current guidelines supporting the use of selective beta(1)-blockers in patients with CVD and especially in heart failure (HF), they are still largely underused, mostly as a consequence of the presence of chronic obstructive pulmonary disease (COPD). In primary care, prevalence of COPD in patients with HF is approximately 25%, and it will rise in the next years. In the general population, only 20% of COPD patients with HF are treated with beta-blockers. beta-Blockers may result in pulmonary adverse effects that are relevant to COPD patients. Bronchoconstriction may be the consequence of: absence of cardioselectivity; loss of cardioselectivity at high doses, and unopposed stimulation of cholinergic muscarinic M(2) receptors. The concern of inducing bronchospasm is the more likely explanation of a poor prescription of beta-blockers in patients with CVD also suffering from COPD. However, under carefully controlled conditions, which include close monitoring of lung function and appropriate selection of the drug and titration of the dose on a case-by-case basis, selective beta(1)-blockers can be safely administered to most patients with COPD. Pneumologists and cardiologists should develop a detailed and standardized protocol to guide the use of selective beta(1)-blockers in everyday practice, which could significantly reduce the physicians' mistrust of beta-blockers in COPD patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054001413

Download citation: RISBibTeXText

PMID: 20639691

DOI: 10.1159/000318583


Related references

Beta blockers in asthma and COPD--a therapeutic dilemma?. Pneumologie 55(2): 53-56, 2001

Systemic corticosteroids in COPD. An unresolved clinical dilemma. Chest 110(4): 867-869, 1996

Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest 127(3): 818-824, 2005

Beta blockers and COPD. Chest 78(5): 675-676, 1980

COPD and beta-blockers. Comprehensive Therapy 8(9): 3-5, 1982

Beta-blockers and depression. The clinician's dilemma. JAMA 267(13): 1826-1827, 1992

No beta blockers without a COPD anamnesis. Nederlands Tijdschrift Voor Geneeskunde 129(6): 265-267, 1985

Can beta-blockers be used for people with COPD?. Drug and Therapeutics Bulletin 49(1): 2-5, 2011

Beta-blockers and COPD: the show must go on. European Respiratory Journal 48(3): 600-603, 2016

Use of beta blockers in patients with COPD. Thorax 63(4): 296-298, 2008

Even in COPD beta blockers can be administered - but not all. Mmw Fortschritte der Medizin 157(18): 44, 2015

Beta-blockers in patients with asthma and COPD. 2012

Treatment with beta blockers in people with COPD. Bmj 342: D2655, 2011

Beta-blockers associated with reduced all-cause mortality in COPD. 2012

Contraindications to beta blockers are eroding more and more - even in COPD. Praxis 100(17): 1055-1056, 2011